Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn about a recent article by Pishoy Gouda etv al., published in JACC: Advances, adding:
“Apixaban 2.5 mg BID isn’t simply the ‘safer dose.’
It’s the correct dose for a specific patient population.
A new JACC: Advances analysis of real-world apixaban prescribing caught my attention:
61% of patients receiving reduced-dose apixaban did not meet the labeled criteria for dose reduction.
For stroke prevention in nonvalvular atrial fibrillation, the rule is worth remembering:
Think 2 of 3
- Age 80 years or older
- Weight 60 kg or less
- Serum creatinine 1.5 mg/dL or higher
Meet at least 2 of 3, use apixaban 2.5 mg BID
Meet 0 or 1, use generally 5 mg BID, per labeling.
Why does inappropriate dose reduction happen?
The reasoning is often understandable:
- ‘They’re elderly.’
- ‘They’re frail.’
- ‘Their kidneys aren’t great.’
- ‘I’m worried about bleeding.’
Those factors absolutely deserve clinical consideration.
But they don’t independently rewrite the dose-reduction criteria.
And importantly, this study did not show that inappropriate dose reduction provided a major-bleeding advantage.
It also did not prove that every off-label dose reduction causes stroke – this was observational evidence, and that distinction matters.
What it does reveal is a persistent medication-safety opportunity.
This is anticoagulation stewardship at its most practical:
- Verify the indication.
- Verify the dose.
- Check current weight and renal function.
- Reassess as patients age and clinical circumstances change.
And perhaps most importantly:
Don’t confuse dose reduction with risk reduction.
Sometimes the safest anticoagulant dose isn’t the lower dose.
It’s the correct dose.
Important: these criteria apply to NVAF dosing. Apixaban 2.5 mg BID has other evidence-based indications, including extended VTE therapy.”
Title: Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation
Authors: Pishoy Gouda, Josephine Harrington, Kelly Arps, Gretchen Sanders, Anqi Chen, Karen Chiswell, Paul Hofmann, Keith Marsolo, Kirubel Asfaw, Rosa Coppolecchia, John H. Alexander, Jonathan Piccini, Christopher B. Granger, Heidi T. May, Elizabeth Chrischilles, Benjamin A. Steinberg, Alanna M. Chamberlain, Jeffrey VanWormer, W. Schuyler Jones, Manesh R. Patel
Other posts featuring Edward Lee Carter on Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH